Please enable JavaScript.
Coggle requires JavaScript to display documents.
Rizatriptan - Coggle Diagram
Rizatriptan
-
-
major adverse effects
-
sensation of burning, warmth, heat, numbness, tightness, tingling
-
-
heaviness, tightness, or pressure in the chest and/or neck
-
-
pharmacokinetics
-
-
-
-
Approximately 14% of an oral dose is excreted in urine as unchanged rizatriptan while 51% is excreted as indole acetic acid metabolite, indicating substantial first pass metabolism.
drug interactions
Rapid following oral administration. Bioavailability is 45%. Food has no effect on the bioavailability of rizatriptan. However, administering rizatriptan with food will delay by 1 hour the time to reach peak plasma concentration. The rate of absorption is not affected by the presence of a migraine attack.
benzodiazepine
The risk or severity of adverse effects can be increased when Rizatriptan is combined with 1,2-Benzodiazepine.
-
MOA inhibitors may causes serious, possibly fatal drug interactions
-
mechanism of action
-
stimulation of presynaptic 5-HT1D receptors, which serves to inhibit both dural vasodilation and inflammation
direct inhibition of trigeminal nuclei cell excitability via 5-HT1B/1D receptor agonism in the brainstem
asoconstriction of meningeal, dural, cerebral or pial vessels as a result of vascular 5-HT1B receptor agonism
-
-